OKYO Pharma

OKYOPhase 2

OKYO Pharma is dedicated to developing innovative treatments for debilitating ocular conditions, specifically Neuropathic Corneal Pain (NCP) and Dry Eye Disease (DED). The company's lead asset, Urcosimod, leverages a proprietary Membrane Anchored Peptide (MAP) technology to enhance drug residence time and potency at the ocular surface. OKYO has achieved a key milestone by receiving FDA IND clearance for Urcosimod in NCP, positioning it as a first-mover in a space with no approved therapies.

Market Cap

$80.7M

Focus

Small Molecules

OKYO · Stock Price

USD 1.572.05 (-56.63%)

Historical price data

AI Company Overview

Technology Platform

Membrane Anchored Peptide (MAP) platform, which creates lipidated peptide drugs to enhance ocular residence time and potency by targeting the chemerin receptor (ChemR23) to resolve inflammation and neuropathic pain.

Pipeline Snapshot

2 drugs in pipeline

Drug	Indication	Stage
OK-101 + Placebo	Dry Eye Disease	Phase 2
OK-101 0.05% + OK-101 0.1% + Placebo	Neuropathic Pain	Phase 2

Opportunities

The primary growth opportunity lies in addressing the completely unmet need in Neuropathic Corneal Pain (NCP), a greenfield market.

Additionally, capturing even a small share of the massive $5+ billion Dry Eye Disease market with a novel, differentiated therapy could generate significant revenue.

The company's first-mover status in NCP provides a potential regulatory and commercial advantage.

Risk Factors

Key risks include clinical trial failure of the lead asset Urcosimod, which the company is wholly dependent on.

As a pre-revenue firm, it faces ongoing funding and dilution risk to finance development.

In the crowded DED market, it also faces significant commercial competition from large, established players.

Competitive Landscape

For NCP, OKYO faces no direct approved competitors, competing primarily against off-label systemic drugs. In Dry Eye Disease, it will compete against major players like Bausch + Lomb (Xiidra®) and AbbVie (Restasis®). Differentiation is based on Urcosimod's novel chemerin receptor agonist mechanism targeting both inflammation and pain.